APIM THERAPEUTICS IS A BIOTECHNOLOGY COMPANY DEDICATED TO THE DEVELOPMENT OF NOVEL ANTI-CANCER AGENTS TARGETING THE DNA DAMAGE RESPONSE.

At APIM THERAPEUTICS AS we focus on the development and commercialization of novel combinatorial therapies in cancer cells. Our approach is based on targeting PCNA, a master “hub” protein regulating cell responses to stress e.g. upon DNA Damage Response triggered by  several anti-cancer agents (chemotherapy & targeted agents). Through development of first-in-class peptide drugs which contain a novel PCNA-interacting Peptide Motif termed APIM, the company offers a novel intervention point allowing cancer-specific tumor cell elimination. The company's lead drug, ATX-101, is set to enter the clinic in 2016.

 

DRUG PIPELINE

Drug PipelineAPIM Therapeutics AS is developing a pipeline of peptide drugs that target PCNA-dependent stress responses in cancer cells. Our lead compound, ATX-101, has shown proof-of-concept in multiple preclinical in vitro and in vivo cancer models.

Learn More

 

ABOUT US

APIM Therapeutics AS is a venture capital supported spin off from the Norwegian University of Science and Technology (NTNU) at Trondheim, Norway.

Learn More

 

APIM THERAPEUTICS SNAPSHOT

APIM Therapeutics SnapshotDownload this pdf for a short company summary.

View recent scientific posters presented in the TAT 2016 and AACR Precision series 2016 conferences.